Search Result

Results for "

HIV virions

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HIV (13) HIV Protease (1) Bacterial (1) Environmental Pollutants (1) HCV (1) hnRNP (1) HSV (2) Interleukin Related (1) SOD (1)
By Research Areas:	Cancer (2) Infection (12) Inflammation/Immunology (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Targets Recommended: HIV Integrase HIV HIV Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-125474

Carrageenan 1 Publications Verification	Environmental Pollutants HIV HSV	Infection Cancer
Carrageenan is an antiviral and anticancer agent. Carrageenan inhibits herpes simplex virus (HSV), HIV, and hepatitis A virus (HAV) by directly binding to the viral capsid to block the attachment of viruses such as HPV to HSPG factors on the cell surface. Carrageenan delays and arrests cell cycle progression, exhibits cytotoxicity against HeLa cancer cells, and can be applied to studies related to cervical cancer, genital warts, hepatitis A, and other conditions. Carrageenan also induces acute non-immune inflammation, triggers a three-phase inflammatory response involving the release of multiple proinflammatory mediators, and causes persistent edema, hyperalgesia, and neutrophil recruitment in mice .

HY-159828

Dezecapavir VH-499; VH4011499	HIV	Infection
Dezecapavir (VH-499) is a *HIV-1* capsid protein inhibitor. Dezecapavir exhibits picomolar-level antiviral activity against a variety of *HIV-1* laboratory strains and clinical isolates in vitro. Dezecapavir inhibits the early and late stages of the *HIV-1* life cycle, blocking nuclear import, reverse transcript production, virion assembly, maturation, and post-nuclear import/pre-integration replication processes. Dezecapavir can be used in studies related to *HIV-1* infection .

HY-P10310A

F9170 TFA	HIV	Infection
F9170 TFA is an amphipathic peptide with an activity of inactivate *HIV-1 virions. F9170 TFA targets the conserved cytoplasmic tail of HIV*-1 env and disrupts the integrity of the viral membrane. F9170 TFA is able to cross the blood-brain barrier (BBB) .

HY-116282W

Dextran sulfate sodium salt (MW 6500-10000) DSS (MW 6500-10000); DXS (MW 6500-10000)	HIV	Inflammation/Immunology
Dextran sulfate sodium salt (DSS) (MW 6500-10000) is a polymer of dehydrated glucose with a molecular weight of approximately 5000. Dextran sulfate sodium salt with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 6500-10000) has antiviral activity against *HIV-1* and *HIV-2. Dextran sulfate sodium salt (MW 6500-10000) blocks the binding of virions* to CD4 ^⁺ T lymphocytes and inhibits syncytia formation. Dextran sulfate sodium salt (MW 6500-10000) also prevents experimental urolithiasis due to its cytoprotective actions. Moreover, because of its biocompatible and highly charged properties, Dextran sulfate sodium salt (MW 6500-10000) is a suitable choice for pharmaceutical systems .

HY-P10310

F9170	HIV	Infection
F9170 is an amphipathic peptide with an activity of inactivate *HIV-1 virions. F9170 targets the conserved cytoplasmic tail of HIV*-1 env and disrupts the integrity of the viral membrane. F9170 is able to cross the blood-brain barrier (BBB) .

HY-P10653

C5A	HCV HIV	Infection
C5A is a microbicidal peptide, anti-hepatitis C virus (HCV), and anti-HIV agent. C5A disrupts the membrane integrity of the *HIV* virion as well as the integrity of the conical capsid core that surrounds the viral genome. C5A inhibits in vitro infectivity of a broad range of primary HIV isolates in various primary target cells. C5A protects mice against vaginal and rectal HIV challenges .

HY-P5363A

PAP 248-286 acetate Prostatic acid phosphatase (248-286) acetate	HIV	Infection
PAP 248-286 (Prostatic acid phosphatase (248-286)) acetate is a biological active peptide. PAP (248-286) acetate is a semen-derived enhancer of viral infection (SEVI) factor found in semen. This peptide greatly increases HIV infection through enhanced virion attachment to target cells. .

HY-P5363

PAP 248-286 Prostatic acid phosphatase (248-286)	HIV	Infection
PAP 248-286 (Prostatic acid phosphatase (248-286)) is a biological active peptide. PAP (248-286) peptide is a semen-derived enhancer of viral infection (SEVI) factor found in semen. This peptide greatly increases HIV infection through enhanced virion attachment to target cells .

HY-124870

N.41	HIV	Infection
N.41 is an antiviral agent. N.41 protects APOBEC3G (an antiviral factor) from HIV Vif protein-mediated degradation. N.41 inhibits the Vif-A3G interaction and increases cellular A3G levels and incorporation of A3G into virions, thereby attenuating virus infectivity in a Vif-dependent manner. N.41 inhibits HIV-1 viral replication in PBMCs (IC₅₀: 8.4 μM) .

HY-120157

Vif-ElonginC interaction inhibitor 1	HIV	Infection
Vif-ElonginC interaction inhibitor 1 (compound VEC-5) is a potent Vif inhibitor. Vif-ElonginC interaction inhibitor 1 can restrict *HIV-1* in Vif-nonpermissive cells. Vif-ElonginC interaction inhibitor 1 can protect A3G, APOBEC3C (A3C), and APOBEC3F (A3F) from Vif-mediated degradation and drastically inhibit Vif function through blocking the interaction between Vif and ElonginC. Vif-ElonginC interaction inhibitor 1 enhances A3G incorporation into HIV-1 virions to reduce viral infectivity .

HY-126120

BILA 1906 BS	HIV HIV Protease	Infection
BILA 1906 BS is a *HIV* protease inhibitor. BILA 1906 BS prevents *HIV-1* replication via inhibition of viral protease-mediated cleavage of Gag and Gag-Pol polyprotein precursors during virion maturation. BILA 1906 BS blocks maturation of p24 proteins in wild-type HIV-1, impairing polyprotein processing and viral maturation. BILA 1906 BS can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .

HY-182514

BMMP	HIV hnRNP	Infection Cancer
BMMP is an anti-HIV-1 agent and hnRNP M modulator. BMMP modulates hnRNP M function to suppress CD44 mRNA expression. BMMP induces abnormal uncoating of the HIV viral core at the post-entry step. BMMP suppresses migration of TGF-β-stimulated lung carcinoma cells. BMMP suppresses HIV-1 reverse transcription and replication without inhibiting virion release. BMMP exerts anti-HIV-1 activity via a mechanism distinct from CA protein-binding heterocyclic compounds. BMMP can be used for the research of human immunodeficiency virus infection and non-small cell lung cancer .

HY-W587782

Nonoxynol-9	HIV SOD HSV Interleukin Related Bacterial	Infection
Nonoxynol-9 is a nonionic detergent. Nonoxynol-9 inhibits SOD activity. Nonoxynol-9 exhibits activity against diverse microbes and pathogens. Nonoxynol-9 can be used for the research of HIV infection .

Cat. No.	Product Name

HY-L027

Antiviral Compound Library	1,180 compounds
Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs. MCE designs a unique collection of 1,180 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.

Antiviral Compound Library

1,180 compounds

Viruses are much simpler organisms than bacteria, and they are made from protein substances and nucleic acid. Despite the fact that the exact mechanism of infection is extremely specific to each type of virus, the general scheme of infection can be represented in the following manner: A virus is absorbed at the surface of a host cell and then permeates through the membrane, where it releases nucleic acid from its protein protection. Then the viral nucleic acid begins to replicate, and transcription of the viral genome takes place either in the cytoplasm, or in the nucleus of the host cell. As a result of these events, a large amount of viral nucleic acid and protein are made to make new generations of virions. Therefore, one mechanism of action of antiviral drugs is to interfere with the ability of a virus to get into a target cell. A second mechanism of action is to target the processes that synthesize virus components after a virus invades a cell, such as nucleotide or nucleoside analogs.

MCE designs a unique collection of 1,180 anti-virus compounds that target several viruses, including SARS-CoV, HBV, HCV, HIV, HSV and Influenza Virus. It’s an effective tool for anti-virus drug discovery.

Cat. No.	Product Name	Type

HY-125474

Carrageenan 1 Publications Verification	Biochemical Assay Reagents
Carrageenan is an antiviral and anticancer agent. Carrageenan inhibits herpes simplex virus (HSV), HIV, and hepatitis A virus (HAV) by directly binding to the viral capsid to block the attachment of viruses such as HPV to HSPG factors on the cell surface. Carrageenan delays and arrests cell cycle progression, exhibits cytotoxicity against HeLa cancer cells, and can be applied to studies related to cervical cancer, genital warts, hepatitis A, and other conditions. Carrageenan also induces acute non-immune inflammation, triggers a three-phase inflammatory response involving the release of multiple proinflammatory mediators, and causes persistent edema, hyperalgesia, and neutrophil recruitment in mice .

Carrageenan

1 Publications Verification

Biochemical Assay Reagents

Carrageenan is an antiviral and anticancer agent. Carrageenan inhibits herpes simplex virus (HSV), HIV, and hepatitis A virus (HAV) by directly binding to the viral capsid to block the attachment of viruses such as HPV to HSPG factors on the cell surface. Carrageenan delays and arrests cell cycle progression, exhibits cytotoxicity against HeLa cancer cells, and can be applied to studies related to cervical cancer, genital warts, hepatitis A, and other conditions. Carrageenan also induces acute non-immune inflammation, triggers a three-phase inflammatory response involving the release of multiple proinflammatory mediators, and causes persistent edema, hyperalgesia, and neutrophil recruitment in mice .

HY-116282W

Dextran sulfate sodium salt (MW 6500-10000) DSS (MW 6500-10000); DXS (MW 6500-10000)	Biochemical Assay Reagents
Dextran sulfate sodium salt (DSS) (MW 6500-10000) is a polymer of dehydrated glucose with a molecular weight of approximately 5000. Dextran sulfate sodium salt with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 6500-10000) has antiviral activity against *HIV-1* and *HIV-2. Dextran sulfate sodium salt (MW 6500-10000) blocks the binding of virions* to CD4 ^⁺ T lymphocytes and inhibits syncytia formation. Dextran sulfate sodium salt (MW 6500-10000) also prevents experimental urolithiasis due to its cytoprotective actions. Moreover, because of its biocompatible and highly charged properties, Dextran sulfate sodium salt (MW 6500-10000) is a suitable choice for pharmaceutical systems .

Dextran sulfate sodium salt (MW 6500-10000)

DSS (MW 6500-10000); DXS (MW 6500-10000)

Biochemical Assay Reagents

Dextran sulfate sodium salt (DSS) (MW 6500-10000) is a polymer of dehydrated glucose with a molecular weight of approximately 5000. Dextran sulfate sodium salt with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 6500-10000) has antiviral activity against HIV-1 and HIV-2. Dextran sulfate sodium salt (MW 6500-10000) blocks the binding of virions to CD4 ^⁺ T lymphocytes and inhibits syncytia formation. Dextran sulfate sodium salt (MW 6500-10000) also prevents experimental urolithiasis due to its cytoprotective actions. Moreover, because of its biocompatible and highly charged properties, Dextran sulfate sodium salt (MW 6500-10000) is a suitable choice for pharmaceutical systems .

Cat. No.	Product Name	Target	Research Area

HY-P10310A

F9170 TFA	HIV	Infection
F9170 TFA is an amphipathic peptide with an activity of inactivate *HIV-1 virions. F9170 TFA targets the conserved cytoplasmic tail of HIV*-1 env and disrupts the integrity of the viral membrane. F9170 TFA is able to cross the blood-brain barrier (BBB) .

HY-P10310

F9170	HIV	Infection
F9170 is an amphipathic peptide with an activity of inactivate *HIV-1 virions. F9170 targets the conserved cytoplasmic tail of HIV*-1 env and disrupts the integrity of the viral membrane. F9170 is able to cross the blood-brain barrier (BBB) .

HY-P10653

C5A	HCV HIV	Infection
C5A is a microbicidal peptide, anti-hepatitis C virus (HCV), and anti-HIV agent. C5A disrupts the membrane integrity of the *HIV* virion as well as the integrity of the conical capsid core that surrounds the viral genome. C5A inhibits in vitro infectivity of a broad range of primary HIV isolates in various primary target cells. C5A protects mice against vaginal and rectal HIV challenges .

HY-P5363A

PAP 248-286 acetate Prostatic acid phosphatase (248-286) acetate	HIV	Infection
PAP 248-286 (Prostatic acid phosphatase (248-286)) acetate is a biological active peptide. PAP (248-286) acetate is a semen-derived enhancer of viral infection (SEVI) factor found in semen. This peptide greatly increases HIV infection through enhanced virion attachment to target cells. .

HY-P5363

PAP 248-286 Prostatic acid phosphatase (248-286)	HIV	Infection
PAP 248-286 (Prostatic acid phosphatase (248-286)) is a biological active peptide. PAP (248-286) peptide is a semen-derived enhancer of viral infection (SEVI) factor found in semen. This peptide greatly increases HIV infection through enhanced virion attachment to target cells .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.